RETRA

Overview

RETRA is a RIPK1/RIPK3/MLKL and p73 activator. RETRA mediates plasma membrane disruption, induces ROS accumulation, triggers early mitochondrial hyperpolarization, and synergistically drives necroptosis . RETRA inhibits cancer cells carrying mutant p53 via a p73-dependent salvage pathway. RETRA can be used in research related to cervical cancer and cancers with mutant p53.

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Cervical Cancer | Products > Disease Areas > Urogenital Cancer | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Immunology/Inflammation | Products > Signaling Pathways > NF-κB | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Reactive Oxygen Species (ROS) | Products > Signaling Pathways > Necroptosis | Products > Signaling Pathways > MDM-2/p53 | Products > Signaling Pathways > RIP kinase | Products > Signaling Pathways > Mixed Lineage Kinase

Product Information

• Catalog No.: HY-108636
• CAS No.: 1036069-26-7
• Molecular Formula: C11H11NO3S2
• Molecular Weight: 269.34
• Purity: 99.42%
• Storage: -20°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
• Availability: In-stock

Source

Original product source